In ObSeva's latest attempt to stay afloat, the Swiss biotech offloads one of 2 remaining assets

Only two months after a ruthless restructuring saw the company cut staff by 70% and focus much of its remaining resources on preterm labor treatment ebopiprant, ObsEva is now selling off that potential therapy as well.